AAIC and Ohara invest USD 3 million in Revital Healthcare for syringe capacity expansion

Asia Africa Investment and Consulting Pte Ltd (AAIC) and Ohara Pharmaceutical Company Ltd jointly invested USD 3 million into Revital Healthcare EPZ Ltd to boost its syringe production capacity from 75 million to over 400 million annually. The investment was announced on 2021-12-21.

“This will see means the Kilifi-based manufacturer, one of 25 auto-disable syringe manufacturers pre-qualified by the World Health Organization (WHO) and the only one in Africa enhance its production capacity from 75 million syringes to more than 400 million annually.”the-star.co.ke

• 3 sources
• the-star.co.keKenyan medical firm receives Sh339 million boostDec 21, 2021
• the-star.co.keKenyan medical firm receives Sh339 million boostDec 21, 2021
• the-star.co.keKenyan medical firm receives Sh339 million boostDec 21, 2021

Summarized from public sources; check the original articles before acting on it.